Literature DB >> 11358653

Effects of different levels of hypercapnic hyperoxia on tumour R(2)* and arterial blood gases.

S P Robinson1, L M Rodrigues, F A Howe, M Stubbs, J R Griffiths.   

Abstract

The hypercapnia induced by carbogen (95% O(2)/5% CO(2)) breathing, which is being re-evaluated as a clinical radiosensitiser, causes patient discomfort and hence poor compliance. Recent preclinical and clinical studies have indicated that the CO(2) content might be lowered without compromising increased tumour oxygenation and radiosensitisation. This preclinical study was designed to see if lower levels of hypercapnia could evoke similar decreases in the transverse relaxation rate R(2)* of rodent tumours to those seen with carbogen breathing. The response of rat GH3 prolactinomas to 1%, 212% and 5% CO(2) in oxygen, and 100% O(2) breathing, was monitored by non-invasive multi-gradient echo MRI to quantify R(2)*. As the oxygenation of haemoglobin is proportional to the blood p(a)O(2) and therefore in equilibrium with tissue pO(2), R(2)* is a sensitive indicator of tissue oxygenation. Hyperoxia alone decreased R(2)* by 13%, whilst all three hypercapnic hyperoxic gases decreased R(2)* by 29%. Breathing 1% CO(2) in oxygen evoked the same decrease in R(2)* as carbogen. The DeltaR(2)* response is primarily consistent with an increase in blood oxygenation, though localised increases in tumour blood flow were also identified in response to hypercapnia. The data support the concept that levels of hypercapnia can be reduced without loss of enhanced oxygenation and hence potential radiotherapeutic benefit.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11358653     DOI: 10.1016/s0730-725x(01)00230-2

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  15 in total

1.  Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging.

Authors:  Simon P Robinson; Tammy L Kalber; Franklyn A Howe; Dominick J O McIntyre; John R Griffiths; David C Blakey; Lynsey Whittaker; Anderson J Ryan; John C Waterton
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

2.  Enhanced uptake of ifosfamide into GH3 prolactinomas with hypercapnic hyperoxic gases monitored in vivo by (31)P MRS.

Authors:  Loreta M Rodrigues; Simon P Robinson; Paul M J McSheehy; Marion Stubbs; John R Griffiths
Journal:  Neoplasia       Date:  2002 Nov-Dec       Impact factor: 5.715

3.  Effect of breathing a hyperoxic hypercapnic gas mixture on the oxygenation of meningiomas; preliminary results.

Authors:  Janneke Schuuring; Mark Rijpkema; Hans Bernsen; Pieter Bernsen; Richard van der Maazen; Johannes Kaanders; Albert van der Kogel; Arend Heerschap
Journal:  J Neurooncol       Date:  2002-04       Impact factor: 4.130

4.  Application of an exogenous hyperoxic contrast agent in MR mammography: initial results.

Authors:  Dorothee R Fischer; Jürgen R Reichenbach; Alexander Rauscher; Jan Sedlacik; Werner A Kaiser
Journal:  Eur Radiol       Date:  2004-09-22       Impact factor: 5.315

5.  Hypofractionated Conformal Radiotherapy (HCRT) for primary and metastatic lung cancers with small dimension : efficacy and toxicity.

Authors:  Maria Alessandra Mirri; Giorgio Arcangeli; Marcello Benassi; Annelisa d'Angelo; Valentina Pinzi; Mauro Caterino; Massimo Rinaldi; Anna Ceribelli; Lidia Strigari
Journal:  Strahlenther Onkol       Date:  2009-02-18       Impact factor: 3.621

6.  Monitoring Treatment Efficacy of Antiangiogenic Therapy Combined With Hypoxia-Activated Prodrugs Online Using Functional MRI.

Authors:  Mengjie Ma; Jianye Liang; Dong Zhang; Xi Xu; Qingqing Cheng; Zeyu Xiao; Changzheng Shi; Liangping Luo
Journal:  Front Oncol       Date:  2021-04-30       Impact factor: 6.244

7.  Effect of hyperoxia and hypercapnia on tissue oxygen and perfusion response in the normal liver and kidney.

Authors:  Hai-Ling Margaret Cheng
Journal:  PLoS One       Date:  2012-07-06       Impact factor: 3.240

8.  Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging.

Authors:  S P Robinson; D J O McIntyre; D Checkley; J J Tessier; F A Howe; J R Griffiths; S E Ashton; A J Ryan; D C Blakey; J C Waterton
Journal:  Br J Cancer       Date:  2003-05-19       Impact factor: 7.640

9.  Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis.

Authors:  V Kostourou; S P Robinson; J E Cartwright; G St J Whitley
Journal:  Br J Cancer       Date:  2002-09-09       Impact factor: 7.640

10.  High-resolution structural and functional assessments of cerebral microvasculature using 3D Gas ΔR2*-mMRA.

Authors:  Chien-Hsiang Huang; Chiao-Chi V Chen; Tiing-Yee Siow; Sheng-Hsiou S Hsu; Yi-Hua Hsu; Fu-Shan Jaw; Chen Chang
Journal:  PLoS One       Date:  2013-11-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.